Screener Summaries Updates Institutions Sign In More Updates › Leadership & Pay › NVCR Leadership & Pay · Sep 9, 2026
Timothy Scannell retired from the Board of NovoCure Limited effective September 2, 2026 NVCR NovoCure Ltd
Timothy Scannell retired from the Board of NovoCure Limited effective September 2, 2026. His departure followed five years of service and did not result from any disagreement with management. NovoCure Limited develops medical devices for cancer treatment.
More from NovoCure Ltd NovoCure reports Q3 net revenue of $193 million, raises full-year guidance to $736M-$743M Oct 29, 2026 Japan approves NovoCure's Optune Pax for unresectable locally advanced pancreatic cancer Oct 1, 2026 Novocure reported second quarter 2026 net revenues of $183.6 million, a 16% year-over-year increase, driven by global… Jul 23, 2026 On June 30, 2026, NovoCure announced that its Optune Pax device received a CE Mark for treating adult patients with… Jun 30, 2026 NovoCure Limited announced top-line results from its Phase 3 TRIDENT trial, which failed to demonstrate a… Jun 18, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
